The technology we have developed consists of a method capable of modulating the expression of specific target genes in deep-tissue cells from an exogenous signal of high safety and precision. The present invention is composed by: 1. a nanoparticle capable of converting the ultrasonic signal into a chemical signal: 2. an energy system, capable of stimulating the nanoparticle to produce Reactive Oxygen Species (ROS), and 3. a system of ROS-responsive gene constructs (ROS-ATF) capable of finely modulating the expression of key genes associated with chronic inflammatory diseases, such as chronic degenerative spine disease (LBP). Our technology may provide a new therapeutic strategy to counter chronic degenerative diseases through the modulation of the expression of key mediators involved in inflammatory “pathways.”
This technology enables manipulation of the gene regulatory network (GRN) with high spatial precision—down to single-cell level—and fully predetermined timing. It relies on three components: (1) nanoparticles (NPs), (2) acoustic pressure waves, and (3) engineered gene constructs (ROS-ATFs), which together act as a logical AND gate to activate the target gene. NPs and constructs are delivered to the target organ, and ultrasound stimulation triggers transcription under strict control. Spatial precision prevents off-target effects, while temporal control minimizes interference in complex biological networks, allowing clinically meaningful modulation of gene activation—a key factor in chronic degenerative diseases.
Italy